Productoverview
- NameKainicacid
- ShortdescriptionPrototypic,selectivekainatereceptoragoNIST.Potentexcitantandneurotoxin.
- BIOLOGicaldescription
Prototypic,selectivekainatereceptor(KAR)agonist.AnalogofL-Glutamate.
Potentexcitantandneurotoxin(shows~30-foldmoreneurotoxicpotencythanL-Glutamate).Inducesvariouschangesinvivoincludingrecurrentseizures,behaviouralchanges,oxidativestress,glialactivationandselectiveneuronaldeath.
KainicacidexertsitsneuroexcitatoryactionbybindingtoglutamatereceptorstocauseCa2+influxandtriggeringsubsequentexcitotoxicneuronaldeathpathwaycascades.Kainicacidiswidelyusedtomodelvariousneurodegenerativediseasesandepilepsy.
- BiologicalactionAgonist
- Purity>98%
- Customercomments
WetestedtheKainicacidandweareveryhappywithit.HelloBioKainicacidwasusedat25mg/kgi.p.andsuccessfullyinducedstatusepilepticus.Verifiedcustomer,CNRS,France
- OurproductsinactionSubmitYourCitationNow
Images
Properties
- Chemicalname(2S,3S,4S)-Carboxy-4-(1-methylethenyl)-3-pyrrolidineaceticacid
- MolecularWeight213.23
- Chemicalstructure
- MolecularFormulaC10H15NO4
- CASNumber487-79-6
- PubChemidentifier10255
- SMILESCC(=C)[C@H]1CNC([C@H]1CC(=O)O)C(=O)O
- SourceExtractedfromdigineasimplex
- InChiInChI=1S/C10H15NO4/c1-5(2)7-4-11-9(10(14)15)6(7)3-8(12)13/h6-7,9,11H,1,3-4H2,2H3,(H,12,13)(H,14,15)/t6-,7+,9-/m0/s1
- InChiKeyVLSMHEGGTFMBBZ-OOZYFLPDSA-N
- MDLnumberMFCD00150833
- AppearanceWhitesolid
Applications
- Applicationnotes
Thekainatereceptor(KAR)agonistkainicacidinducesneuronaloscillationsinthegammafrequencyband(35-100Hz).KARactivationleadstosynchronousactivityofexcitatoryandinhibitorynetworkfiring.Kainicacidiscommonlyusedatconcentrationsof400-600nMtoinduceoscillationsinacutebrainslices. Ataconcentrationof550nM,kainicacidfromHelloBioinducesastronggammafrequencyneuronaloscillation(approx.35Hz)withintheCA3regionoftherathippocampus(seeFig1above). Oscillationswereabolishedfollowingkainicacidwashout.
#Protocol1:Oscillationsassay
- Acuterathippocampalsliceswereplacedinaninterfacechamberandheldat30°CwithaglassrecordingelectrodeplacedintheCA3regionofthehippocampus.
- Controlbasalactivitywasrecordedfor1hrinthepresenceofaCSFbeforecontinuousperfusionofaCSFcontainingkainicacidat550nMtoinduceoscillations.
- OscillationactivitywasrecordedonceoscillationshadstABIlised(~2-3hours).
- KainicacidwasthenwashedoutandreplacedwithcontrolaCSF.
- Datawereanalysedtocreateapowerspectrumoftheoscillation.
StoringandUsingYourProduct
- StorageinstructionsRoomtemperature
- SolubilityoverviewSolubleinwater(25mM,gentlewarming)
- ImportantThisproductisforRESEARCHUSEONLYandisnotintendedfortherapeuticordiagnosticuse.Notforhumanorveterinaryuse.
ReferencesforKainicacid
Kainicacid-mediatedexcitotoxicityasamodelforneurodegeneration.
WangQetal(2005)MolNeurobiol31(1-3):3-16.PubMedID:15953808Distinctmodulationoftheendocannabinoidsystemuponkainicacid-inducedinvivoseizuresandinvitroepileptiformbursting.
FezzaFetal(2014)MolCellNeurosci62:1-9.PubMedID:25064144Identificationandcharacterizationoftheligandbindingsubunitofakainicacidreceptorusingmonoclonalantibodiesandpeptidemapping.
HampsonDRetal(1989)JBiolChem264(22):13329-35.PubMedID:2546953Pharmacologicalcharacterizationofglutamatergicagonistsandantagonistsatrecombinanthumanhomomericandheteromerickainatereceptorsinvitro.
Altetal(2004)Neuropharmacology46(6):793-806PubMedID:15033339